stocks logo

ROIV Valuation

Roivant Sciences Ltd
$
10.660
+0.240(+2.300%)

Is ROIV Overvalued?

ROIV is now in the Fair zone, suggesting that ROIV current forward PE ratio of -9.39 is considered Fair compare with the five-year average of -6.96.
P/E
EV/EBITDA
P/S
P/B
bubble
P/E

ROIV Competitors Valuation Multiple

P/E
EV/EBITDA
P/S

P/E Multiple

Earnings Growth
Market Cap
stocks logo
ROIV.O
Roivant Sciences Ltd
loss
Average P/E: 44.49
-103.57%
7.61B
stocks logo
MDGL.O
Madrigal Pharmaceuticals Inc
loss
52.26%
7.69B
stocks logo
JAZZ.O
Jazz Pharmaceuticals PLC
5.81
118.52%
8.38B
stocks logo
LEGN.O
Legend Biotech Corp
loss
-99.54%
6.83B
stocks logo
ASND.O
Ascendis Pharma A/S
loss
40.19%
9.28B
stocks logo
RGEN.O
Repligen Corp
83.16
8.44B

ROIV Revenue Breakdown & PS Ratio Relation

Currency:USD
By Business
By Region
Composition (FY2025Q1)
Name
Revenue
Percentage
Biotechnology & Medical Research
55.13M
--
VTAMA
55.13M
--

ROIV FAQs

Is ROIV currently overvalued based on its P/E ratio?

According to the provided data, ROIV's 5-year historical average forward P/E ratio is -6.96. ROIV forward P/E ratio is -9.39, which is categorized as Fair.

What is the significance of the EV/EBITDA ratio for ROIV?

How has ROIV's Price to Sales (PS) ratio evolved?

What are the key indicators to watch for ROIV's financial performance?

ROIV PE Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average PE
-6.96
Current PE
-9.39
Overvalued PE
-2.24
Undervalued PE
-11.69

ROIV EV/EBITDA Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average EV
-3.10
Current EV
-2.40
Overvalued EV
-0.57
Undervalued EV
-5.64

ROIV P/S Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Overvalued
5Y Average PS
53.33
Current PS
96.57
Overvalued PS
90.05
Undervalued PS
16.61

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is ROIV undervalued?Is ROIV overvalued compared to its competitors?